Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

Serum ocrelizumab concentration was strongly associated with B-cell count. Measurement of ocrelizumab drug concentrations and ADAs could play an important role to further personalise treatment and predict the start of B-cell repopulation.